CN112661793A - Ruthenium-artesunate complex and preparation method and application thereof - Google Patents
Ruthenium-artesunate complex and preparation method and application thereof Download PDFInfo
- Publication number
- CN112661793A CN112661793A CN202011515343.3A CN202011515343A CN112661793A CN 112661793 A CN112661793 A CN 112661793A CN 202011515343 A CN202011515343 A CN 202011515343A CN 112661793 A CN112661793 A CN 112661793A
- Authority
- CN
- China
- Prior art keywords
- artesunate
- ruthenium
- complex
- reaction
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004991 artesunate Drugs 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000010668 complexation reaction Methods 0.000 title description 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims abstract description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000007806 chemical reaction intermediate Substances 0.000 claims description 7
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical class [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- 229910019891 RuCl3 Inorganic materials 0.000 claims description 3
- -1 ammonium hexafluorophosphate Chemical compound 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 3
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 16
- 239000012327 Ruthenium complex Substances 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 229910052707 ruthenium Inorganic materials 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 102000002490 Rad51 Recombinase Human genes 0.000 description 3
- 108010068097 Rad51 Recombinase Proteins 0.000 description 3
- 108700000707 bcl-2-Associated X Proteins 0.000 description 3
- 102000055102 bcl-2-Associated X Human genes 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003303 ruthenium Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229940125650 NAMI-A Drugs 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- JSGHQDAEHDRLOI-UHFFFAOYSA-N oxomalononitrile Chemical compound N#CC(=O)C#N JSGHQDAEHDRLOI-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The ruthenium-artesunate complex can improve the uptake of cells to artesunate by utilizing the ruthenium complex, and after the ruthenium complex and the artesunate enter the cells, the ruthenium complex and the artesunate cooperatively play an anti-tumor role.
Description
Technical Field
The invention relates to a ruthenium-artesunate complex, a preparation method thereof and an anti-tumor effect thereof, belonging to the field of chemical biology.
Background
The ruthenium complex is in a 6-coordination octahedral configuration, and the unique three-dimensional structure of the ruthenium complex can provide various coordination modes, so that the ruthenium complex can be better matched with a three-dimensional structure cavity of protein, and the selectivity of the metal complex to the protein is improved; the ruthenium polypyridine complex also has abundant photochemical and photophysical characteristics, and can be used for conveniently carrying out cell positioning and mechanism research. Clarke et al discovered the complex Cl (NH) in 19803)5Ru (III) has anticancer activity on tumor-bearing rats. Zasinovich et al found cis- [ RuCl ] containing DMSO ligands2(DMSO)4]Has activity on mouse lung cancer cells, the activity of the medicine is slightly weaker than that of cisplatin, but the side effect of the medicine is smaller. Currently, two ruthenium complexes NAMI-A, KP1019 have successfully entered clinical trials. Coordination-saturated ruthenium polypyridine complexes are another class of compounds that have been extensively studied with anticancer promise. Polypyridine refers to pyridine derivatives having a multidentate coordination structure, which, when coordinated to ru (ii), can impart photoluminescent properties to the complex by metal-ligand charge transfer. And related documents report that ruthenium polypyridine complexes play an antitumor role through DNA damage and mitochondrial pathways. Gasser et al reported that a ruthenium polypyridine complex with carboxyl can specifically target tumor cell mitochondria, has an antitumor activity equivalent to that of cisplatin, and can overcome the drug resistance of cisplatin. The ruthenium complex belongs to an ionic compound, the solubility of the ruthenium complex is improved compared with that of an organic compound, the hydrophilic-lipophilic coefficient of the compound, the mode of entering cells and the kinetics of the compound are greatly influenced, and the uptake amount and the uptake mode of the metal complex by the cells can be improved.
Artesunate is one of artemisinin derivatives, and has higher antimalarial activity than artemisinin. Artesunate is reported in the literature to have anti-tumor activity. Chulwon et al reported that artesunate can inhibit the growth of tumor cells and induce apoptosis in a mouse model of chronic myeloid leukemia. Meanwhile, artesunate can effectively reduce the level of RAD51 in ovarian cancer cells and glioma cells (RAD51 is a key protein for mediating the sensitivity of cancer cells to DNA damaging agents), and further enhance the killing power of the DNA damaging agents on the cancer cells. However, the artesunate tablet has poor water solubility, obvious first-pass effect and liver drug enzyme induction effect when being taken orally, and low bioavailability; and the artesunate powder injection has the advantages of fast blood concentration reduction after intravenous injection, half-life period of about 30 minutes, fast in vivo clearance rate, and the above defects limit the application of the artesunate powder injection in various diseases.
The metal-organic drug complex can improve the uptake of small molecule drugs by cells by using the metal complex, and even solve the drug resistance problem of drugs. Guo Zijia et al reported that tetravalent platinum-artesunate complex targeting RAD51 has strong antitumor activity against BRCA mutated ovarian cancer and breast cancer. Aspirin is bonded to tetravalent platinum by Liu Yang Zhong and Liu Yang teams to synthesize the Asplatin, and the compound can effectively overcome the drug resistance of cisplatin. The ruthenium polypyridine complex has high lipid solubility, and the combination of the ruthenium polypyridine complex and the artesunate can improve the amount of the artesunate taken by cells. After entering cells, the ruthenium complex and the artesunate cooperatively play an anti-tumor role. Meanwhile, the ruthenium polypyridine complex has photochemical and photophysical characteristics, and can be used for conveniently carrying out cell positioning and mechanism research.
Disclosure of Invention
The invention aims to provide a ruthenium-artesunate complex, a preparation method thereof and application of the ruthenium-artesunate complex as an anti-tumor drug.
The invention provides a ruthenium-artesunate complex with a chemical formula of [ Ru (DIP) ]2bpy(4-CH3-4'-CH2OART)](PF6)2The structure is shown as the following formula I:
the invention also provides a preparation method of the ruthenium-artesunate complex, which comprises the following specific steps:
s1, 7.6729mmol DIP and 3.836mmol RuCl3·nH2O and 38.36mmol lithium chloride are placed in a three-neck flask, 11mL of N, N-dimethylformamide is added, reaction is carried out for 8h at 153 ℃ under the protection of nitrogen, after the reaction is finished, the reaction solution is dropwise added into 150mL of glacial acetone,then, the mixture is placed in a refrigerator at 4 ℃ overnight, filtered, washed alternately with water precooled at 4 ℃ and acetone to obtain cis- [ Ru (DIP)2Cl2]·2H2O；
S2, 0.3144mmol of cis- [ Ru (DIP) obtained from S12Cl2]·2H2Placing O and 0.3144mmol of 4-hydroxymethyl-4 '-methyl-2-2' -bipyridine into a three-neck flask, adding 100mL of ethanol water solution with volume fraction of 75%, reacting at 85 ℃ for 8h under the protection of nitrogen, fully concentrating the reaction solution to 10mL after the reaction is finished, adding 1.2576mmol of ammonium hexafluorophosphate solid, ultrasonically precipitating a large amount of precipitate, performing suction filtration and vacuum drying, and separating and purifying the precipitate by silica gel column chromatography with acetonitrile/water/saturated sodium nitrate solution as eluent to obtain a reaction intermediate [ Ru (DIP)2bpy(4-CH3-4'-CH2OH)](PF6)2，Ru-1；
S3, placing 0.1592mmol of reaction intermediate obtained in S2, 15.92mmol of ART, 0.2388mmol of dehydrating agent and 0.1592mmol of catalyst in a 250mL round bottom flask, adding 100mL of ultra-dry dichloromethane, reacting at room temperature for 3 days, concentrating reaction liquid to 5mL, dropwise adding the reaction liquid into 20mL of diethyl ether, precipitating a large amount of precipitate, performing suction filtration and vacuum drying, and separating and purifying the obtained crude product by silica gel column chromatography with dichloromethane/methanol solution as eluent to obtain ruthenium-artesunate complex [ Ru (DIP) ]2bpy(4-CH3-4'-CH2OART)](PF6)2，Ru-2。
The dehydrating agent is dicyclohexylcarbodiimide.
The catalyst is 4-dimethylamino pyridine.
The acetonitrile/water/saturated sodium nitrate solution is obtained by mixing acetonitrile, water and a saturated sodium nitrate solution according to the volume ratio of 100:9: 1.
The dichloromethane/methanol solution is obtained by mixing dichloromethane and methanol according to the volume ratio of 60: 1.
The DIP is phenanthroline; 4-hydroxymethyl-4 '-methyl-2-2' -bipyridine as bpy (4-CH)3-4'-CH2OH); ru-1 is a reaction intermediate; ru-2 is a ruthenium-artesunate complex; ART is artesunate.
The invention also provides application of the ruthenium-artesunate complex in preparing antitumor drugs, and researches show that the ruthenium-artesunate complex has good antitumor activity.
The anti-tumor effect of the ruthenium-artesunate complex is verified by an MTT colorimetric method, and the tumor cells are HeLa (human cervical cancer cell strain), HepG2 (human hepatoma cell strain) and A549R (drug-resistant human lung cancer cell strain). The uptake level and the uptake mechanism of the ruthenium-artesunate complex in tumor cells and Western Blot research are carried out in HeLa cells.
Compared with the prior art, the invention has the following excellent effects:
(1) the compound with the anti-tumor effect is a ruthenium complex which has a multi-coordination configuration and can be modified by different ligands to realize the specific combination of the compound and a corresponding substrate.
(2) The ruthenium polypyridine complex has high lipid solubility, can improve the uptake of cells to artesunate by combining the ruthenium polypyridine complex with the artesunate, and synergistically plays an anti-tumor role after entering the cells.
Drawings
FIG. 1 is a drawing of compound Ru-11H-NMR spectrum;
FIG. 2 is an ESI-MS spectrum of compound Ru-1;
FIG. 3 is a drawing of compound Ru-21H-NMR spectrum;
FIG. 4 is an ESI-MS spectrum of compound Ru-2;
FIG. 5 is a confocal laser microscopy study of Ru-2 uptake in HeLa cells;
FIG. 6 shows confocal laser microscopy on the uptake mechanism of Ru-2 in HeLa cells;
FIG. 7 shows the study of anti-tumor mechanism of Ru-2 in HeLa cells by Western Blot.
Detailed Description
The technical solution of the present invention is further described below with reference to the accompanying drawings and specific examples, but the scope of the present invention is not limited thereto, and the materials used in the examples can be obtained by market purchase or prepared by conventional methods without specific description.
Example 1
7.6729mmol DIP, 3.836mmol RuCl3·nH2Placing O and 38.36mmol of lithium chloride in a three-neck flask, adding 11mL of N, N-dimethylformamide, reacting for 8h at 153 ℃ under the protection of nitrogen, dropwise adding the reaction solution into 150mL of glacial acetone after the reaction is finished, then placing in a refrigerator at 4 ℃ overnight, performing suction filtration, and alternately washing with water and acetone which are used for precooling at 4 ℃ to obtain cis- [ Ru (DIP)2Cl2]·2H2O；
0.3144mmol of cis- [ Ru (DIP)2Cl2]·2H2Placing O and 0.3144mmol of 4-hydroxymethyl-4 '-methyl-2-2' -bipyridine into a three-neck flask, adding 100mL of ethanol water solution with volume fraction of 75%, reacting at 85 ℃ for 8h under the protection of nitrogen, fully concentrating the reaction solution to 10mL after the reaction is finished, adding 1.2576mmol of ammonium hexafluorophosphate solid, ultrasonically precipitating a large amount of precipitate, performing suction filtration and vacuum drying, and separating and purifying the precipitate by silica gel column chromatography with acetonitrile/water/saturated sodium nitrate solution (100:9:1, v/v/v) as eluent to obtain a reaction intermediate [ Ru (DIP) ]2bpy(4-CH3-4'-CH2OH)](PF6)2Ru-1, 83.64% yield.
FIGS. 1 and 2 show the compound Ru-11H-NMR and ESI-MS spectra; as shown in the drawings,1H NMR(600MHz,d6-DMSO)δ8.82(d,J＝18.8Hz,2H),8.35(s,2H),8.25(d,J＝21.3Hz,6H),7.95(d,J＝5.1Hz,2H),7.89–7.49(m,24H),7.45(s,1H),7.36(s,1H),5.78(s,1H),4.77(s,2H),2.56(s,3H)。MS(ESI):m/z:965.3[M-2PF6-H]+。
placing 0.1592mmol reaction intermediate, 15.92mmol ART, 0.2388mmol dehydrating agent dicyclohexylcarbodiimide and 0.1592mmol catalyst 4-dimethylamino pyridine in a 250mL round bottom flask, adding 100mL ultra-dry dichloromethane, reacting at room temperature for 3 days, concentrating the reaction solution to 5mL after the reaction is finished, dropwise adding the reaction solution into 20mL diethyl ether, precipitating a large amount of precipitate, filtering, and vacuum dryingSeparating and purifying the obtained crude product by silica gel column chromatography with dichloromethane/methanol solution (60:1, v/v) as eluent to obtain ruthenium-artesunate complex [ Ru (DIP)2bpy(4-CH3-4'-CH2OART)](PF6)2Ru-2, yield 48.5%.
FIGS. 3 and 4 show the compounds Ru-21H-NMR and ESI-MS spectra; as shown in the drawings,1H NMR(600MHz,DMSO)δ8.87–8.80(m,2H),8.34(s,2H),8.28–8.20(m,6H),7.95(d,J＝5.3Hz,2H),7.82(d,J＝5.6Hz,1H),7.77(s,2H),7.72–7.62(m,21H),7.47(d,J＝5.9Hz,1H),7.38(d,J＝5.8Hz,1H),5.63(d,J＝4.2Hz,1H),5.50(d,J＝8.3Hz,1H),5.37(s,2H),2.76(dd,J＝18.2,4.4Hz,4H),2.57(s,3H),2.25(s,1H),2.14(s,1H),1.96(d,J＝14.3Hz,1H),1.79(s,1H),1.48(s,3H),1.34(s,3H),1.21(d,J＝9.4Hz,3H),1.14(s,1H),0.85(s,4H),0.67(s,3H)。MS(ESI):m/z:666.2[M-2PF6]2+。
example 2
The ruthenium-artesunate complex is tested by an anti-tumor activity experiment:
HepG2, A549R and HeLa cells were cultured in DMEM medium containing 10% fetal calf serum and 1% penicillin-streptomycin solution (10% fetal calf serum and 1% penicillin-streptomycin by volume) at 37 deg.C with 5% CO2Culturing in a cell culture box, digesting the cells into single cell suspension with 0.25% trypsin by mass percent, counting the living cells by adopting a blood counting chamber, and adjusting the concentration of the living cells to be 5 multiplied by 104PermL, inoculating in 96-well culture plate, culturing for 24 hr at 160 μ L per well, adding different amounts of drugs to final concentrations of 100 μ M, 50 μ M, 25 μ M, 12.5 μ M, 6.25 μ M, 3.125 μ M, and 1.5625 μ M, standing at 37 deg.C and containing 5% CO2The incubation was carried out for 48 hours, MTT (20. mu.L/well) was added 4 hours before the end, the supernatant was discarded 4 hours after the end, DMSO (150. mu.L/well) was added, and the mixture was shaken for 15 minutes, after which the absorbance at a wavelength of 570nm was measured.
The cells are divided into a blank control group, a positive control group, a negative control group and an experimental group, wherein the blank control group is a culture medium containing 1% DMSO, the positive control group adopts cisplatin (cissplatin), the negative control group adopts Ru-1, Ru-1+ ART and ART, and the experimental group adopts Ru-2.
IC50The concentration is calculated by the sps and is the half inhibitory effective concentration.
The test results are shown in table 1 below, and the experimental data are the average values obtained after three parallel experiments.
As can be seen from Table 1, the IC of Ru-2 was determined at the same concentration50The lowest, it indicates that Ru-2 has the best anti-tumor effect.
TABLE 1
Example 3
The uptake of the ruthenium-artesunate complex in HeLa cells was investigated, and this example shows the uptake of the ruthenium-artesunate complex in HeLa cells by confocal laser microscopy:
HeLa cells were cultured in 35mm Corning confocal laser culture dishes, and when the density was 70%, 5. mu.M Ru-2 was added thereto and incubated for 1 hour, 2 hours, 3 hours, and 4 hours, respectively, and then washed twice with PBS and immediately observed with a confocal laser microscope.
As a result of the study, as shown in FIG. 5, the amount of Ru-2 uptake by the cells increased in a time-dependent manner.
Example 4
The uptake mechanism of the ruthenium-artesunate complex in HeLa cells was studied, and this example investigated the uptake mechanism of the ruthenium-artesunate complex in HeLa cells by confocal laser microscopy:
HeLa cells were cultured in 35mm Corning confocal laser culture dishes, and when the density was 70%, 30. mu.M of CCCP (CCCP, carbonyl cyanide metachlorobenzhydrazone, metabolic inhibitor) and 50. mu.M of Chloroquine (Chloroquine, endocytosis inhibitor) were added for preincubation for 1 hour, after which the culture solution was replaced with a culture solution containing 5. mu.M of Ru-2 (DMEM as the medium), and after further incubation for 4 hours, the cells were washed twice with PBS and immediately observed with a laser confocal microscope.
The research result is shown in fig. 6, after being treated by 4 ℃ or a metabolic inhibitor CCCP, the uptake efficiency of the HeLa cells to the complex is reduced, and after being pretreated by an endocytosis inhibitor chloroquine, the uptake efficiency of the HeLa cells to the complex is not obviously changed; the research result shows that the ruthenium-artesunate complex enters HeLa cells through an energy-dependent pathway.
Example 5
The research on the anti-tumor mechanism of the ruthenium-artesunate complex comprises the following steps:
HeLa cells were cultured in a 60mm Corning dish, and when the density thereof reached 70%, Ru-2 (the concentration of Ru-2 was set to 0. mu.M, 4. mu.M, 6. mu.M, 8. mu.M, respectively) was added, and the mixture was incubated in an incubator at 37 ℃ for 24 hours, after which RIPA lysate was added, the cells were lysed on ice, centrifuged, and the supernatant was collected and the total protein concentration was measured with a BCA protein assay kit.
Separating target protein by SDS-polyacrylamide gel electrophoresis, transferring the target protein to a PVDF membrane, and soaking the PVDF membrane in a confining liquid and shaking for 2h at room temperature. Followed by shaking with the corresponding primary antibody (. beta. -actin,. beta. -caspase-3, PARP, Bax, Bcl-2) overnight at 4 ℃ and finally incubation with horseradish peroxidase-labeled secondary antibody at room temperature for 1 h. Signal detection was performed using ECL chemiluminescent substrate kit.
caspase-3 is a critical executive molecule for apoptosis; PARP is a marker of apoptosis; bcl-2 can enhance the resistance of cells to most DNA damage factors and inhibit apoptosis caused by chemotherapeutic drugs; the Bax gene is the main apoptosis gene of human body, and the encoded Bax protein can form heterodimer with Bcl-2 to generate repression on the Bcl-2.
As shown in FIG. 7, after Ru-2 treatment, caspase-3 cleavage can be induced, and PARP is sheared, so that Bcl-2 expression in cells can be reduced, and Bax expression can be improved.
The experimental results show that the ruthenium-artesunate complex can play the role of anti-tumor by inducing HeLa cells to undergo apoptosis.
Claims (7)
1. The ruthenium-artesunate complex is characterized in that the chemical formula is [ Ru (DIP) ]2bpy(4-CH3-4'-CH2OART)](PF6)2The structure is shown as the following formula I:
2. the preparation method of the ruthenium-artesunate complex as claimed in claim 1, which comprises the following steps:
s1, 7.6729mmol of bathophenanthroline and 3.836mmol of RuCl3·nH2Placing O and 38.36mmol of lithium chloride in a three-neck flask, adding 11mL of N, N-dimethylformamide, reacting for 8h at 153 ℃ under the protection of nitrogen, dropwise adding the reaction solution into 150mL of glacial acetone after the reaction is finished, then placing in a refrigerator at 4 ℃ overnight, performing suction filtration, and alternately washing with water and acetone which are used for precooling at 4 ℃ to obtain cis- [ Ru (DIP)2Cl2]·2H2O；
S2, 0.3144mmol of cis- [ Ru (DIP) obtained from S12Cl2]·2H2Placing O and 0.3144mmol of 4-hydroxymethyl-4 '-methyl-2-2' -bipyridine into a three-neck flask, adding 100mL of ethanol water solution with volume fraction of 75%, reacting at 85 ℃ for 8h under the protection of nitrogen, fully concentrating the reaction solution to 10mL after the reaction is finished, adding 1.2576mmol of ammonium hexafluorophosphate solid, ultrasonically precipitating a large amount of precipitate, performing suction filtration and vacuum drying, and separating and purifying the precipitate by silica gel column chromatography with acetonitrile/water/saturated sodium nitrate solution as eluent to obtain a reaction intermediate [ Ru (DIP)2bpy(4-CH3-4'-CH2OH)](PF6)2；
S3, placing 0.1592mmol of reaction intermediate, 15.92mmol of artesunate, 0.2388mmol of dehydrating agent and 0.1592mmol of catalyst in a 250mL round-bottom flask, adding 100mL of super-dry dichloromethane, reacting at room temperature for 3 days, concentrating the reaction solution to 5mL after the reaction is finished, dropwise adding the reaction solution into 20mL of diethyl ether, precipitating a large amount of precipitate, performing suction filtration and vacuum drying, and separating and purifying the obtained crude product by silica gel column chromatography with dichloromethane/methanol solution as eluent to obtain a ruthenium-artesunate complex [ Ru (DIP)2bpy(4-CH3-4'-CH2OART)](PF6)2。
3. The method for producing a ruthenium-artesunate complex according to claim 2, wherein the dehydrating agent is dicyclohexylcarbodiimide.
4. The method for producing a ruthenium-artesunate complex according to claim 2, wherein the catalyst is 4-dimethylaminopyridine.
5. The method for preparing a ruthenium-artesunate complex as claimed in claim 2, wherein the acetonitrile/water/saturated sodium nitrate solution is obtained by mixing acetonitrile, water, and a saturated sodium nitrate solution at a volume ratio of 100:9: 1.
6. The method for producing a ruthenium-artesunate complex according to claim 2, wherein the dichloromethane/methanol solution is prepared by mixing dichloromethane and methanol at a volume ratio of 60: 1.
7. The use of the ruthenium-artesunate complex according to claim 1 for the preparation of an antitumor agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011515343.3A CN112661793B (en) | 2020-12-21 | 2020-12-21 | Ruthenium-artesunate complex and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011515343.3A CN112661793B (en) | 2020-12-21 | 2020-12-21 | Ruthenium-artesunate complex and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112661793A true CN112661793A (en) | 2021-04-16 |
| CN112661793B CN112661793B (en) | 2022-03-18 |
Family
ID=75406547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011515343.3A Expired - Fee Related CN112661793B (en) | 2020-12-21 | 2020-12-21 | Ruthenium-artesunate complex and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112661793B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292605A (en) * | 2021-06-15 | 2021-08-24 | 中山瑞德生物科技有限公司 | Erianin ruthenium complex and preparation method and pharmaceutical application thereof |
| CN114907417A (en) * | 2022-06-10 | 2022-08-16 | 中国人民解放军空军军医大学 | Tetravalent platinum ternary complex containing artesunate and non-steroidal anti-inflammatory drug and preparation method and application thereof |
| CN115611951A (en) * | 2022-10-13 | 2023-01-17 | 江苏南创化学与生命健康研究院有限公司 | TREM2 inhibitor for tumor chemoimmunotherapy and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906667A (en) * | 2016-04-26 | 2016-08-31 | 中国科学院长春应用化学研究所 | Chemical substance with anticancer activity and preparation method and application thereof |
| CN110437285A (en) * | 2019-07-16 | 2019-11-12 | 中国中医科学院中药研究所 | Qinghaosu ruthenium metal complex and preparation method thereof and medical usage |
-
2020
- 2020-12-21 CN CN202011515343.3A patent/CN112661793B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906667A (en) * | 2016-04-26 | 2016-08-31 | 中国科学院长春应用化学研究所 | Chemical substance with anticancer activity and preparation method and application thereof |
| CN110437285A (en) * | 2019-07-16 | 2019-11-12 | 中国中医科学院中药研究所 | Qinghaosu ruthenium metal complex and preparation method thereof and medical usage |
Non-Patent Citations (1)
| Title |
|---|
| RUI-RONG YE等: "Mitochondria-targeted artesunate conjugated cyclometalated iridium(III) complexes as potent anti-HepG2 hepatocellular carcinoma agents", 《METALLOMICS》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113292605A (en) * | 2021-06-15 | 2021-08-24 | 中山瑞德生物科技有限公司 | Erianin ruthenium complex and preparation method and pharmaceutical application thereof |
| CN113292605B (en) * | 2021-06-15 | 2022-07-12 | 中山瑞德生物科技有限公司 | Erianin ruthenium complex and preparation method and pharmaceutical application thereof |
| CN114907417A (en) * | 2022-06-10 | 2022-08-16 | 中国人民解放军空军军医大学 | Tetravalent platinum ternary complex containing artesunate and non-steroidal anti-inflammatory drug and preparation method and application thereof |
| CN114907417B (en) * | 2022-06-10 | 2024-04-19 | 中国人民解放军空军军医大学 | Tetravalent platinum ternary complex containing artesunate and nonsteroidal anti-inflammatory drug as well as preparation method and application thereof |
| CN115611951A (en) * | 2022-10-13 | 2023-01-17 | 江苏南创化学与生命健康研究院有限公司 | TREM2 inhibitor for tumor chemoimmunotherapy and application thereof |
| CN115611951B (en) * | 2022-10-13 | 2023-09-15 | 江苏南创化学与生命健康研究院有限公司 | TREM2 inhibitor for tumor chemoimmunotherapy and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112661793B (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112661793B (en) | Ruthenium-artesunate complex and preparation method and application thereof | |
| Kamatchi et al. | Ruthenium (II)/(III) complexes of 4-hydroxy-pyridine-2, 6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro | |
| Qin et al. | In vitro and in vivo antitumor activities of three novel binuclear platinum (II) complexes with 4′-substituted-2, 2′: 6′, 2 ″-terpyridine ligands | |
| CN111171080B (en) | High-efficiency low-toxicity anticancer compound synthesized by autocatalysis in cells and living bodies and synthesis method thereof | |
| CN111393483B (en) | Tetravalent platinum naphthalimide complex, preparation method and application thereof | |
| CN107955042B (en) | Platinum complex with anticancer activity, preparation method and application | |
| CN105949222B (en) | A kind of water-soluble acylhydrazone class Schiff porphyrin metal Cu (II) complexs and its synthesis and application | |
| Al-Jaroudi et al. | Synthesis, spectroscopic characterization, X-ray structure and electrochemistry of new bis (1, 2-diaminocyclohexane) gold (III) chloride compounds and their anticancer activities against PC3 and SGC7901 cancer cell lines | |
| CN109796503B (en) | Preparation method of dinuclear metallocene ruthenium complex and application of dinuclear metallocene ruthenium complex in tumor resistance | |
| CN113072595B (en) | Low-toxicity Pt complex and preparation method and application thereof | |
| Gao et al. | Two new palladium (II) complexes: Synthesis, characterization and their interaction with HeLa cells | |
| CN104230998A (en) | Mitochondrion-targeted iridium-N-heterocycle carbene complex as well as preparation method and application thereof | |
| Wang et al. | Antitumor activity and DNA binding studies on rare earth metal complexes with all-trans retinoic acid and l-glutamic acid | |
| CN110128482B (en) | Preparation method and application of novel Pt (IV) complex with tumor targeting function | |
| Gürbüz et al. | Silver (I) N-heterocyclic carbene complexes: Synthesis, characterization and cytotoxic properties | |
| Liu et al. | The anticancer application of half-sandwich iridium (iii) ferrocene-thiosemicarbazide Schiff base complexes | |
| CN107827934B (en) | Tetravalent platinum complex with anticancer activity, preparation method and application | |
| Kamatchi et al. | Impact of chelation on anticancer activities of organometallic ruthenium (ii) complexes containing 2, 5-di (1 H-pyrazol-1-yl)-1, 4-benzoquinone: synthesis, structure, DNA/protein binding, antioxidant activity and cytotoxicity | |
| CN112940059B (en) | Glycosyl modified naphthalimide-polyamine conjugate, preparation method and application thereof | |
| CN114524853A (en) | All-trans retinoic acid-aryl metal complex, preparation method and application | |
| Belousoff et al. | Syntheses, structures and hydrolytic properties of copper (II) complexes of asymmetrically N-functionalised 1, 4, 7-triazacyclononane ligands | |
| CN109705158A (en) | A kind of independence pair center Ag complexs and preparation method thereof and anticancer activity evaluation | |
| CN112876414A (en) | Polyamine-modified naphthalimide conjugate, and preparation method and application thereof | |
| CN103483388A (en) | Norharman-ruthenium (II) polypyridine complex with antitumour activity | |
| Sharma et al. | Design, synthesis and in-vitro cytotoxicity of novel platinum (II) complexes with phthalate as the leaving group |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220318 |